Planet MicroCap spoke with Seth Lederman, Founder and CEO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all):

[0:44] Quick overview and history of Tonix Pharmaceuticals Holding Corp.
[1:57] What makes Tonix Pharmaceuticals Holding Corp. unique and different compared to their peers
[3:54] Seth Lederman's background
[5:14] Goals for 2024

For more information about Tonix Pharmaceuticals Holding Corp., please visit: https://www.tonixpharma.com/

Tonix Pharmaceuticals Holding Corp. will be presenting at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024. Register to participate here: https://planetmicrocapshowcase.com/

The interview may contain forward looking statements about Tonix Pharmaceuticals Holding Corp. See Tonix Pharmaceuticals Holding Corp.'s periodic filings with the Securities and Exchange Commission for more complete information.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya1, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction as well as fibromyalgia-type Long COVID. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

Subscribe NOW to Planet MicroCap: http://bit.ly/1Q5Yfym

Get more Planet MicroCap:
Website: https://planetmicrocap.com/
Follow Planet MicroCap:   / planetmicrocap  
Like Planet MicroCap:   / planetmicrocap  
Follow Planet MicroCap on LinkedIn:   / plan.  .

Planet MicroCap is the Official YouTube Channel for the MicroCap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!